Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Legend Biotech Highlights CARVYKTI® and Allogeneic CAR-T Data at ASH 2025
Leads Biolabs Showcases Five Hematologic Malignancy Studies at ASH 2025
RSV Impacts Multiple Myeloma Care by Causing Treatment Delays, Not Death Risk
Caribou Biosciences Shares Surge on Promising Early Cancer Trial Results
Bridging Therapeutic Gaps in RRMM: Advanced Strategies After Frontline Failure
Legend Biotech to Present Ten Studies at 67th ASH Annual Meeting
Personalized Treatment Sequencing Strategies for Relapsed or Refractory Multiple Myeloma
Eddie CEddie Cliff reviews twliff reviews two decades of myeloma RCTs for drug development insights.
Improved therapies uplift myeloma patients despite research funding cuts and disparities.
Robert Orlowski suggests the November 10 Myeloma Paper of the Day.
Dr. Jakubowiak discusses ATLAS trial evaluating Carfilzomib, Lenalidomide, Dexamethasone in myeloma.
Improved treatments uplift multiple myeloma patients despite funding cuts, racial disparities.
AQUILA trial reveals striking benefits of Daratumumab in smoldering multiple myeloma.
Navy veteran overcNavy veteranomes paralysis, achieving remission after a courageous cancer journey.
Expert panel approves Oncopeptides’ Pepaxti as new myeloma treatment option.
Rahul Banerjee discusses optimizing Denosumab dosing strategies in multiple myeloma treatment.
Finding the optimal treatment balance for managing smoldering multiple myeloma effectively.
Immune synergy may reveal why some patients experience long-lasting remission with cilta-cel therapy
Dr Raab discusses using early bispecific combination therapies for myeloma treatment.Dr Raab discuss
Dr Jakubowiak explains how PERSEUS findings guided the ATLAS myeloma trial.
The subcutaneous therapy that significantly reduced patient treatment time by hours.
CAR T REMS elimination significantly reduces operational burden on treatment centers.
CBX7 regulates chemotherapy-induced senescence, influencing treatment response in multiple myeloma.
Rahul Bhargava discusses MRD reporting at 10⁻⁶ sensitivity in myeloma and ALL.
Myeloma Paper of the Day for November 17, suggested by Robert Orlowski.
Dr Raab explains why teclistamab was added to daratumumab-based induction in NDMM.
Rahul Banerjee shares new BJH study insights on functional high-risk myeloma.
Vincent Rajkumar explains why daratumumab should be the first option for high-risk smoldering myelom

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
ASCO 2025:Bispecifics For Front Line Treatment of MM
Targeting Protein Degradation Pathways in Myeloma
ASCO 2025:Four Drug Induction for Multiple Myeloma
Prerna Mewawalla Discusses CAR-T Therapy Advances for Multiple Myeloma at ICE-T
Dr. Raab Discusses Teclistamab-Based Treatment Regimens for Newly Diagnosed Multiple Myeloma Patient
Etentamig Demonstrates Manageable Safety, Minimal Severe Infection Risk in RRMM
Dr. Van Oekelen Explores S100A8/A9’s Role in T-Cell Exhaustion in Myeloma
Termination of Carvykti® Reimbursement Talks Leaves Canadians with Myeloma Devastated
Al-Ola A Abdallah Shares Dr. Mewawalla’s CAR-T Myeloma Advances at ICET Congress
Termination of Carvykti® Reimbursement Talks Leaves Canadians with Myeloma Devastated
Subcutaneous Daratumumab Offers “Win-Win” Benefits for Newly Diagnosed Multiple Myeloma Maintenancev
Robert Orlowski Suggests September 29th Myeloma Paper of the Day
Raising Awareness and Promoting Self-Advocacy in Managing Multiple Myeloma
Clinical Features, Treatment Responses, and Outcomes in Light Chain Multiple Myeloma
Dr. Robert Orlowski, MM Research Vice Chair, MD Anderson Cancer Center
Managing and Addressing Early Toxicity Concerns with Talquetamab Treatment
Dr. Rahul Banerjee’s Six Most Notable Presentations from IMS 2025
Population-Based Study on Causes of Death in Waldenström Macroglobulinemia Patients
Exploring Novel RRMM Therapies: ADCs, Bispecific Antibodies, and CAR T
Optimizing Sequencing Strategies and Patient Selection for Bispecific Antibodies in RRMM
Dr. Yee Discusses Daratumumab, Lenalidomide, Ixazomib, and Dexamethasone in Myeloma
Subcutaneous D-Kd versus Kd in RRMM patients: LYNX study
ASCO 2025: Novel Therapeutic Approaches
Celmods in Multiple Myeloma
Teclistamab combination therapies show promising results in frontline multiple myeloma.
Multiple myeloma cell and gene therapy market poised for rapid growth.
Racial and ethnic minorities face ongoing disparities in BCMA CAR T access.
Myeloma Paper of the Day, October 13, recommended by Robert Orlowski.
CELMoDs may enhance T-cell therapies for lasting remission in myeloma.
Vincent Rajkumar emphasizes the need for new myeloma drug classes.
Case report: Early clinical data on CARsgen CT0596 for plasma leukemia.
Systematic prospective study classifies causes of death during multiple myeloma.
C. Ola Landgren shares highlights from the 25th LLM Congress.
Combination therapy may improve AML patient outcomes, increasing treatment options and survival.
C. Ola Landgren welcomes Rafat Abonour and Gil Hevroni to Sylvester.
Myeloma Paper of the Day, October 18, recommended by Robert Orlowski.
Disseminated Bartonella henselae infection reported in relapsed multiple myeloma post-transplant.
DelveInsight’s 2025 report highlights key advances in relapsed refractory myeloma therapeutics.
Bristol-Myers Squibb launches multiple myeloma maintenance study, promising market transformation.
BeOne Medicines progresses Sonrotoclax study, advancing multiple myeloma treatment options.
Pfizer’s Phase 3 Elranatamab study could revolutionize multiple myeloma treatment.
Epigenetic alterations in PHOX2A and CDH2 genes drive myeloma progression.
Experts share key findings and insights from IMS 2025 conference data.
Vincent Rajkumar urges reading NEJM article to master key MGUS concepts.
Pfizer’s Phase 3 Elranatamab study shows promise for multiple myeloma treatment.
Myeloma Paper of the Day, October 27, recommended by Robert Orlowski.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma
Institutional protocols and approaches for bispecific step-up dosing in R/R MM.
Myeloma Paper of the Day, September 1, recommended by Robert Orlowski.
Long non-coding RNA PLUM promotes chemoresistance via PRC2-mediated UPR activation.
Dr. Landgren explains rationale for evaluating Daratumumab with KRd in myeloma.
Strategies for managing infection risk associated with bispecific antibodies in myeloma.
Approaches to effectively manage adverse events linked to GPRC5D.
Pharmacists manage complex protocols in the rapidly evolving multiple myeloma treatments.
Genomic insights reveal the early origins and development of multiple myeloma.
High-risk MDS faces treatment disparities and challenges with patient adherence.
Dr. Dimopoulos compares BVd versus DVd in high-risk relapsed myeloma
ASCO 2025: BCMA CAR-T Cells For Multiple Myeloma and Amyloidosis
Exploring the Clinical Implications of Achieving a Potential “Cure” in Multiple Myeloma
Dr. Popat Discusses Rationale for Evaluating JNJ-5322 in Relapsed/Refractory Myeloma
Gerardo Rodríguez-Lobato Shares Key Insights on CAR-Ts in Myeloma at ITCTC25
Facing cancer with strength and resilience, standing tall on my own.
Al-Ola A Abdallah Announces Prerna Mewawalla Presenting CAR-T Advances in Myeloma
Coach Strives to Raise Awareness and Funds in Fighting Blood Cancer
The Future of Bispecifics: Exploring Earlier Applications and Expanding Potential
Al-Ola A Abdallah Announces Prerna Mewawalla Presenting CAR-T Advances in Myeloma
Supertramp’s Rick Davies Dies at 81 After Multiple Myeloma Battle
Expert roadmap provides guidance for outpatient bispecific antibody treatment in myeloma.
Identifying the primary causes contributing to end-stage multiple myeloma progression.
Patients and clinical trials play key roles in accelerating myeloma research.
Dr. Burke discusses the promising future and potential of trispecific antibodies.
Belantamab plus pomalidomide and dexamethasone improves survival in lenalidomide-refractory myeloma.
IMS 2025: Enhancing Patient Experience via On-Body Injector Isatuximab-Irfc Administration
Upstate woman credits new multiple myeloma treatment for enjoying life.
Real-world data reveal hematologic responses to pacritinib in anemic myelofibrosis patients.
IMS 2025: Pharmacists Enhance Patient Outcomes Through Elranatamab Therapy
Dara-KRd regimen shows extended progression-free survival in newly diagnosed multiple myeloma.
2025 Myeloma Pipeline: 55+ Companies Driving Innovative Clinical Developments

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
ASCO 2025:Durable MRD and Multiple Myeloma
Bridging the gap between academic and community care in myeloma.
REALiTEC study offers real-world insights on BCMA bispecific antibody treatments.
Sustained MRD measurement guides personalized treatment approaches in myeloma therapy.
Determining optimal sequencing approach for cellular therapies in multiple myeloma.
Whole-body MRI detects tiny bone marrow cancer traces in myeloma.
Onco360® chosen as specialty pharmacy partner for LYNOZYFIC™ (linvoseltamab).
Dr Jamroziak discusses daratumumab versus observation in MRD-positive myeloma.
ASCO 2025 ADVANCE Clinical Trial: Dara-KRd vs KRd for MM
Novel CAR T-Cell Therapies Could Outperform Standard Care in Multiple Myeloma
Myeloma Experts Reveal Neutrophils’ Crucial Role and Novel Treatment Approach
Daratumumab Slows Progression, Supports Early MRD-Relapse Intervention in Multiple Myeloma
Early Referral and Patient Education: Preparing Multiple Myeloma Patients for CAR T
ASCO 2025 Insights: Emerging Multiple Myeloma Data and Future Perspectives
Optimizing the Role of Bispecific T-Cell Engagers in Multiple Myeloma
Comparing T-Cell Engager Applications to Standard Therapies in Multiple Myeloma
Shaping the Future of CAR T-Cell Therapy in Multiple Myeloma
Post–CAR T Care in Myeloma: Connecting Academic Centers and Community Practice
ASCO 2025: Trispecifics For Multiple Myeloma
Trispecific Antibody JNJ-5322 Shows Promise in Redefining Relapsed Myeloma Treatment
Dr. Raza Discusses Talquetamab-Teclistamab Combination in Relapsed Myeloma, EMD
Prerna Mewawalla, MD, highlights remaining unmet needs in relapsed/refractory myeloma patients treat
What’s Ahead for CAR T? Emerging Therapies Shaping Relapsed Myeloma
BCMA Therapy Sequencing: Positioning Belantamab in Today’s Relapsed Myeloma Care
GSK Gains EU Approval as Blenrep Combinations Transform Myeloma Treatment
Dr. Mewawalla Discusses Unmet Needs Following Early CAR T in Myeloma
Trispecific Antibody JNJ-5322 Shows Promise in Redefining Relapsed Myeloma Treatment
Long-Term Cilta-Cel Data Suggests Curative Potential in Pretreated Myeloma
From Diagnosis to Strength: A Cyclist’s Inspiring Journey with Myeloma
Advancing Toward More Precise Approaches in Multiple Myeloma Treatment
Targeting Protein Degradation Pathways in Myeloma
Dr. Sidana Discusses Second-Line Cilta-Cel Efficacy in Relapsed Myeloma
Elranatamab, Daratumumab, and Lenalidomide Show Strong Responses in Transplant-Ineligible Myeloma
Dr. Dreyling Discusses Frontline Acalabrutinib Plus BR Efficacy in High-Risk MCL
Prerna Mewawalla, MD, Discusses Unmet Needs After Early-Line CAR-T in Myeloma
Talquetamab as a Real-World Bridging Strategy to CAR T Therapy in Myeloma
Exploring Cilta-Cel’s effectiveness as a second-line therapy for patients with relapsed or refractor
Talquetamab Provides a Safer Bridging Option to CAR T-Cell Therapy in Myeloma
Talquetamab and Teclistamab May Improve Survival in R/R Myeloma Extramedullary Disease
Strategic Application of BCMA and GPRC5D Bispecifics in Relapsed Myeloma
Talquetamab Enables Myeloma Patients to Transition Safely to CAR T-Cell Therapy
Russia Approves First Daratumumab Biosimilar for Treating Multiple Myeloma
Clinical Insights: Evaluating Real-World Data on Bispecifics in Relapsed Myeloma

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
MCH Roundtable: Recent Advances in Newly Diagnosed Multiple Myeloma
MCH RoundTable: Practical Aspects of Treating Newly Diagnosed Multiple Myeloma
MCH Roundtables: The Future of Treatment for Newly Diagnosed Multiple Myeloma
MCH Roundtable: Maintenance Therapy For Multiple Myeloma
MRD Recurrence Found to Occur Before Biochemical Relapse in Myeloma
JNJ-5322 Enhances Efficacy and Reduces Oral Toxicity in Myeloma Treatment
JNJ-5322 Demonstrates Promising Efficacy in Relapsed Multiple Myeloma Patients
Cilta-cel Shows Promising Results in High-Risk Myeloma and EMD Subgroups
Exploring Effective Treatment Strategies for Patients With Multiple Myeloma Today
Linvoseltamab plus Carfilzomib shows high complete response in myeloma.
Home subcutaneous bortezomib may ease care access for veterans.
Hung Trinh: First detailed CAR-T biomonitoring study in myeloma patients
FDA grants accelerated approval to Lynozyfic for relapsed myeloma treatment.
EHA–EMN releases evidence-based guidelines for multiple myeloma care.
ASCO 2025:MIDAS Trial Farewell to Transplantation?
Are We Starting to Cure Multiple Myeloma?
Dr. Voorhees Explores Cilta-Cel’s Clinical Role in Relapsed/Refractory Myeloma
Dr. Voorhees Highlights Long-Term Durability of Cilta-Cel in Myeloma
Dr. Pan Discusses Anito-Cel Therapy in Relapsed/Refractory Myeloma Patients
Dr. Voorhees Highlights Trispecific Antibodies and Frontline CAR T Therapy
Five-Year Data Shows Cilta-Cel’s Lasting Impact in Myeloma: Dr. Voorhees
Dr. Chari Discusses Changing Criteria for Transplant Eligibility in Myeloma
Will Belantamab Mafodotin Receive Another Chance for Myeloma Approval?
Linvoseltamab and Carfilzomib Show Manageable Safety in Relapsed Myeloma.
Dr Krishnan on Elranatamab-Daratumumab-Lenalidomide in Transplant-Ineligible Myeloma.
Mulligan Explores Search for Optimal Drug Combinations in Myeloma Treatment.
Inside the RedirecTT-1 Study for Multiple Myeloma With EMD.
Dr. Mewawalla discusses real-world roles of cilta-cel and ide-cel in R/R myeloma.
International Myeloma Foundation mourns attorney and longtime board member Benson Klein.
Q\&A: Experts discuss key nursing considerations for immune cell therapy.
Dr. Landgren discusses key factors in treating smoldering multiple myeloma today.
Linvoseltamab could enable more accessible multiple myeloma care, says Sundar Jagannath.
CEPHEUS Study: Subgroup Analysis Highlights
Dr. Burke reviews daratumumab therapy for high-risk smoldering multiple myeloma.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
ISB 2001’s Unique Properties May Benefit Relapsed/Refractory Multiple Myeloma Patients
Dr. Richardson Discusses Best Treatment Approaches for 1q-Amplified Myeloma
Dr. Dholaria Explains P-BCMA-ALLO1 Mechanism in Multiple Myeloma Treatment
Dr. Maroto-Martin Explores MZB1 CAR T-Cell Mechanism in Myeloma, Waldenström
Usmani discusses D-VRd's efficacy and safety in NDMM patients ineligible.
Non-BCMA CAR T-cell therapy shows promise in relapsed/refractory myeloma.
CARTITUDE-1: Cilta-cel shows durable, long-term remission in R/R multiple myeloma.
Dr. Dimopoulos discusses Elranatamab with Daratumumab and Lenalidomide therapy.
Linvoseltamab and carfilzomib demonstrate strong efficacy in pretreated RRMM patients.
Dr. Richardson discusses best treatments for 1q-amplified multiple myeloma.
Linvoseltamab and carfilzomib show lasting responses in triple-class myeloma.
Dr. Krishnan explores trispecific antibodies' impact in relapsed myeloma.
Dr. van de Donk discusses JNJ-5322 trial in relapsed myeloma.
Talquetamab/Teclistamab combo delivers strong, lasting responses in RRMM.
Dr. Landgren discusses Dara-KRd efficacy in all myeloma patients.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
‍Dr Farid explores ongoing and future MDC-CAR-BCMA001 trials in myeloma.
Dr. Garfall discusses the reasoning behind the Phase 2 BMT CTN 1902 trial for multiple myeloma.
Dr Bishop explains why Anito-Cel is studied in relapsed myeloma.
Dr. Joseph explores exercise and supportive care in myeloma treatment research.
Dr. Siegel Reviews Mezigdomide Evaluation in Relapsed/Refractory Myeloma Cases
Dr. Sobh Discusses Impact of NSD2 Overexpression in Multiple Myeloma
Dr Sobh discusses NSD2’s role in immune surveillance in myeloma.
Teclistamab shows efficacy after prior BCMA therapy in RRMM.
Dr Maroto-Martin discusses early efficacy of MZB1 CAR T therapy.
CAR T in Myeloma: Anito-cel Challenges and Emerging Treatment Strategies
Dr Maroto-Martin explores MZB1 CAR T-cell therapy for myeloma.
Freeman Discusses What Sets Anito-cel Apart in Myeloma CAR T Therapy
Harnessing Generative AI to Uncover Deeper Insights Into Multiple Myeloma
Dr Sobh discusses targeting NSD2's therapeutic potential in multiple myeloma.
Dr. Fonseca Discusses Treatment Choices for Relapsed/Refractory Myeloma Patients
Dr. Zonder Highlights the Role of Personalized Medicine in Multiple Myeloma
Myeloma community welcomes growing importance of MRD in treatment decisions.

‍The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
‍Arlocabtagene Autoleucel: a GPRC5D-Targeted CAR T-Cell Therapy
Dr. Krishnan discusses T-cell therapies and novel targets in myeloma.
Dr. Zonder highlights the importance of raising awareness in multiple myeloma.
Dr Mateos discusses CARTITUDE-4 long-term OS in refractory myeloma.
Addressing challenges in accessing and prescribing high-cost myeloma treatments.
Dr Farid discusses MDC-CAR-BCMA001 efficacy in myeloma, amyloidosis.
Dr Mateos discusses ongoing cilta-cel research in newly diagnosed myeloma.
Dr Dholaria explores why P-BCMA-ALLO1 is studied in myeloma.
Dr Zonder discusses multiple myeloma epidemiology and its clinical implications.
Dr Zonder emphasizes early myeloma screening for high-risk patients.
Dr Richardson discusses quadruplet regimens for newly diagnosed myeloma patients.
Dr Farid explores MDC-CAR-BCMA001 for relapsed myeloma, amyloidosis treatment.
Dr Mateos explores cilta-cel’s future clinical development in myeloma.

‍The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Teclistamab ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
Latest Advances in Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Case 5: 66-Year-Old With R/R MM Relapse <2 Years Post-ASCT
Emerging Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma
CARTITUDE-4: Managing Late-Stage CAR-T Therapy Toxicities and Challenges
Dr. Garfall explores CAR T-cell therapy for consolidation or maintenance in myeloma.
Future considerations for multiple myeloma treatment advancements and strategies.
KarMMa-3 trial reveals new insights on Ide-Cel therapy in RRMM.
Dr. Phull discusses retrospective analysis rationale for CAR T-cell therapy in R/R myeloma.
Dr. Richter’s Goals for Expanding T-Cell–Redirecting Therapies in Myeloma
Dr. Ruella highlights clinical trial and treatment accessibility for myeloma.
Dr. Richardson discusses triplet regimens' role in newly diagnosed myeloma.
Dr. Koehne discusses the evolution of multiple myeloma treatment paradigms.
test new
‍

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Dr. Shah on IVIG’s Impact on Infection Risk in R/R Myeloma
Selecting Between Guideline-Recommended Treatment Options for Transplant-Eligible Newly Diagnosed Mu
Real-World Observations on CAR T Therapy in Relapsed/Refractory Multiple Myeloma
Dr. Kaddoura on Challenges of Integrating Whole Genome Sequencing in Myeloma
Real-World Observations on CAR T Therapy in Relapsed/Refractory Multiple Myeloma
PERSEUS Trial Highlights: Dara-VRd vs VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert Views on Referrals and Challenges of CAR T in Early R/R MM
Dr. Siegel on the Present and Future Role of Mezigdomide in Multiple Myeloma
Future Directions Post-AURIGA: Daratumumab and Lenalidomide in Multiple Myeloma Treatment
Panelists Discuss Who Shouldn’t Receive Quadruplet CD38 Regimens in NDMM.
Dr. Landgren on Recent Shifts in the Treatment Paradigm for Multiple Myeloma
Optimal Bridging Therapy Strategies for CAR T Treatment in Early R/R MM.
Managing Relapsed/Refractory Multiple Myeloma: Current Approaches and Future Directions in Community
Clinical Perspectives: Identifying Patients Unsuitable for Quadruplet CD38 Regimens in NDMM.
Expert Perspectives: Comparing and Navigating Findings from CEPHEUS and IMROZ Studies.
Dr. Lin Discusses Cilta-Cel for Lenalidomide-Refractory Multiple Myeloma Treatment.
Cilta-Cel in Early Relapsed Myeloma: Emerging CARTITUDE-4 CAR T Data.
Dr. Phull Compares Real-World and Trial Data for CAR T in R/R MM.
Dr. Bishop Discusses Anito-Cel's Potential Impact on Multiple Myeloma Treatment.
Exploring Post-Autologous Transplant Maintenance Strategies in Multiple Myeloma Treatment.
Daratumumab vs Active Monitoring for High-Risk Smoldering Multiple Myeloma
How I Manage POEMS Syndrome
Dr. Joseph discusses the effects of resistance training on fatigue and pain in multiple myeloma.
Dr. Spencer discusses rationale for evaluating novel CAR T-cell product in pancreatic cancer.
Afami-Cel’s potential impact on standard care for R/R cases.
Dr. Albigès on survival outcomes with Cabozantinib, Nivolumab, and Ipilimumab in RCC.
Drs. Al Malki and Auletta discuss PTCy GVHD prophylaxis in HLA-UUMD patients.
Dr. Meric-Bernstam on efficacy and safety of Dato-DXd in urothelial cancer.
Dr. Pothuri discusses the current treatment paradigm in endometrial cancer.
Dr. Shah discusses efficacy data for Zamto-Cel in R/R DLBCL.
Personalized Myelofibrosis Therapy: Key Clinical Trial Insights and Findings
Dr. Gupta on updated Enfortumab Vedotin-Pembrolizumab data in urothelial cancer.
Dr. Merseburger on real-world outcomes of Axitinib-Avelumab in RCC.
Phase III Trial of Daratumumab Plus Lenalidomide vs Lenalidomide and Dexamethasone in Frail Patients With Newly Diagnosed MM
CARTITUDE-4: Cilta-Cel vs Standard Care in Relapsed/Refractory Multiple Myeloma
Overview of Treatment Options for Later-Stage Relapsed/Refractory Multiple Myeloma
Key Highlights of CARTITUDE-4: Cilta-Cel vs. Standard Care in R/R MM
Overview of Treatment for Later-Stage Relapsed/Refractory Multiple Myeloma
New and Evolving Therapies for Patients With Relapsed/Refractory Multiple Myeloma

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Personalized Therapy in Multiple Myeloma
Rosie’s Inspiring Journey Battling Relapsed/Refractory Multiple Myeloma Challenges.
The Future of Bispecific Therapy in Treating Relapsed/Refractory Multiple Myeloma.
Updates on CEPHEUS Trial: Treating Newly Diagnosed Multiple Myeloma.
Evaluating Patient Eligibility for CAR-T Therapy
Dr. Bishop Reviews 34-Month Data on Anitocabtagene in Myeloma.
Introduction to CAR-T Therapy for Earlier Treatment of R/R Myeloma.
Induction Therapy for Newly Diagnosed Multiple Myeloma
Major findings from the PERSEUS and CASSIOPEIA multiple myeloma studies.
Clinical Case: 74-year-old patient with transplant-ineligible NDMM diagnosis.
Life after CAR T: Insights on its promise in myeloma.
Quadruplet therapy for newly diagnosed transplant-ineligible multiple myeloma patients.
CEPHEUS Trial: Updates in Front-line Treatment for Ineligible Myeloma
Key Insights from CARTITUDE-4 Study Presented at ASH 2024
Understanding the CAR-T Therapy Process for Treating Multiple Myeloma Patients
Key Takeaways from the CARTITUDE-4 Study at ASH 2024
Front-Line Treatment Goals for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
CAR-T Therapy: Bridging Strategies for Multiple Myeloma Treatment Advancement
ASH 2024: IVIG Use With Bispecific Antibodies
Systematic Review and Meta-Analysis Findings Presented at ASH 2024
Guideline-Based Treatment Options for Transplant-Ineligible or Deferred NDMM
Treating Newly Diagnosed Multiple Myeloma
Maintenance Therapy For Multiple Myeloma
Essential Insights into CAR-T Therapy Advancements for Multiple Myeloma Treatment
Anti-CD38 Quadruplet Induction Regimens: New Standard for Transplant-Ineligible NDMM
Dr. Ali discusses exploring novel targets beyond BCMA in multiple myeloma.
CAR T-Cell Therapy Referral Process: Contact, Evaluation, and Patient Selection
CEPHEUS Trial: Subcutaneous Dara-VRd vs VRd in Transplant-Ineligible NDMM
CAR T-Cell Therapy Process and Bridging Strategies for Myeloma Treatment
Coordinating Care and Transition Strategies for CAR-T Myeloma Therapy
Future Directions for Front-line Therapy in Transplant-Ineligible Multiple Myeloma
Anti-CD38 Quadruplet Regimens: Emerging Standard of Care in TE NDMM
CAR-T Therapy in Early Relapsed Myeloma: Discussion and Insights
Newly Diagnosed Multiple Myeloma: Practical Approaches to Care
Dr. Rifkin discusses Belantamab Mafodotin's role in relapsed/refractory multiple myeloma.
CAR T and evolving treatment paradigms for early relapsed/refractory multiple myeloma.
Dr. Banerjee discusses bispecific antibody treatment de-escalation strategies in relapsed myeloma.
Clinical perspectives on choosing daratumumab vs isatuximab quadruplet induction regimens.
CAR T and evolving treatment strategies for early relapsed/refractory multiple myeloma.
Strategies for Care Coordination and Transition in CAR-T Therapy
ASH 2024 highlights the GMMG-HD7 study in multiple myeloma research.
CAR-T therapy in early relapsed myeloma: clinical discussion highlights.
CAR T therapy and evolving treatment approaches for early relapsed/refractory MM.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org